Skip to main content
SpringerLink
Log in

Antipsychotic Dosing and Drug Delivery

  • Chapter
  • First Online:
Behavioral Neurobiology of Schizophrenia and Its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 4))

Abstract

This chapter addresses the current state of affairs regarding proposed mechanism of action for antipsychotic medications and how this mechanism relates to dosing and delivery strategies. The initial portion describes the history of antipsychotic medication, including key discoveries that contribute to the dopamine hypothesis of schizophrenia and provide evidence that dopamine D2 receptor antagonism remains the most copasetic explanation for both determination of dose and degree of efficacy for current antipsychotic medications. Early observations regarding the unique properties of clozapine and how those observations led to the misconception and misnomer of atypicality are also discussed. Subsequent sections relate the dosing of available medications using chlorpromazine equivalents, with a discussion of non-D2-related mechanisms to antipsychotic effects. The balance of the chapter explores the temporal pattern of receptor occupancy as a key determinant of antipsychotic effectiveness, noting that continuous infusion would present the optimal method of treatment. In addition to the pharmacodynamic benefits of continuous long-term delivery systems, the incidence, causes, and clinical consequences of poor adherence are addressed. These observations are then discussed in the context of clinical studies and meta-analyses, demonstrating superiority of long-term depot preparations over oral administration. However, despite overwhelming evidence in favor of long-term delivery systems, few options are available to provide such ideal medication delivery profiles. Barriers to creating traditional depot preparations for a large number of antipsychotic agents, as well as efforts to address these limitations with polymer-based microspheres are described. The potential extension of current formulations to very long-term delivery implants using biodegradable and nonbiodegradable platforms is then described. Benefits as well as limitations of such systems are discussed with respect to clinical and ethical issues as well as a brief description of potential regulatory and logistic barriers to developing better delivery options. In summary, this chapter describes the basis for relating the dose of all existing antipsychotic medications to dopamine D2 receptor affinity and the potential contribution of continuous occupancy to enhanced efficacy through superior biological effects and improved adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adams SG Jr, Howe JT (1993) Predicting medication compliance in a psychotic population. J Nerv Ment Dis 181:558–560

    Article  PubMed  Google Scholar 

  • Adams CE, Fenton MK, Quraishi S, David AS (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290–299

    Article  PubMed  CAS  Google Scholar 

  • Adis International Limited (2005) Histrelin Hydrogel Implant – Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424. Drugs RD 6:53–55

    Article  Google Scholar 

  • Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW (2006) Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67:453–460

    Article  PubMed  Google Scholar 

  • Ashburn MA, Stephen RL, Ackerman E, Petelenz TJ, Hare B, Pace NL, Hofman AA (1992) Iontophoretic delivery of morphine for postoperative analgesia. J Pain Symptom Manage 7:27–33

    Article  PubMed  CAS  Google Scholar 

  • Ashby CR Jr, Wang RY (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24:349–394

    Article  PubMed  CAS  Google Scholar 

  • Baldwin CM, Keating GM (2007) Rotigotine transdermal patch: a review of its use in the management of Parkinson’s disease. CNS Drugs 21:1039–1055

    Article  PubMed  CAS  Google Scholar 

  • Barnes DE, Robinson B, Csernansky JG, Bellows EP (1990) Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol Biochem Behav 36:883–887

    Article  PubMed  CAS  Google Scholar 

  • Bergen J, Hunt G, Armitage P, Bashir M (1998) Six-month outcome following a relapse of schizophrenia. Aust N Z J Psychiatry 32:815–822

    Article  PubMed  CAS  Google Scholar 

  • Berkland C, King M, Cox A, Kim K, Pack DW (2002) Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release 82:137–147

    Article  PubMed  CAS  Google Scholar 

  • Bishara D, Taylor D (2008) Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 68:2269–2292

    Article  PubMed  CAS  Google Scholar 

  • Blanco D, Alonso MJ (1998) Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants. Eur J Pharm Biopharm 45:285–294

    Article  PubMed  CAS  Google Scholar 

  • Blom JH, Hirdes WH, Schroder FH, de Jong FH, Kwekkeboom DJ, van’t Veen AJ, Sandow J, Krauss B (1989) Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol Res 17:43–46

    Article  PubMed  CAS  Google Scholar 

  • Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G (2001) Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 62:855–859

    Article  PubMed  CAS  Google Scholar 

  • Borgman RJ (1982) Bioavailability, dosage regimens, and new delivery systems. In: Craig CR, Stitzel RE (eds). Modern pharmacology. Little, Brown and Company, Boston pp 63–74

    Google Scholar 

  • Borison RL, Diamond B, Pathiraja A, Meibach RC (1994) Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 30:193–197

    PubMed  CAS  Google Scholar 

  • Castle DJ, Pantelis C (2003) Comprehensive care for people with schizophrenia living in the community. Med J Aust 178(Suppl 9):S45–S46

    PubMed  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20:140–144

    Article  CAS  Google Scholar 

  • Casper ES, Regan JR (1993) Reasons for admission among six profile subgroups of recidivists of inpatient services. Can J Psychiatry 38:657–661

    PubMed  CAS  Google Scholar 

  • Chan AL, Chien YW, Jin Lin S (2008) Transdermal delivery of treatment for Alzheimer’s disease: development, clinical performance and future prospects. Drugs Aging 25:761–775

    Article  PubMed  CAS  Google Scholar 

  • Cheer SM, Wagstaff AJ (2004) Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 18:173–199

    Article  PubMed  CAS  Google Scholar 

  • Coombes AG, Heckman JD (1992) Gel casting of resorbable polymers. 1. Processing and applications. Biomaterials 13:217–224

    Article  PubMed  CAS  Google Scholar 

  • Conlon L, Fahy TJ, OT R, Gilligan J, Prescott P (2002) Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication. Eur Psychiatry 17:459–465

    Article  PubMed  CAS  Google Scholar 

  • Cormier M, Chao ST, Gupta SK, Haak R (1999) Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. J Pharm Sci 88:1030–1035

    Article  PubMed  CAS  Google Scholar 

  • Cramer JR, Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201

    PubMed  CAS  Google Scholar 

  • Csernansky JG, Bellows EP, Barnes DE, Lombrozo L (1990) Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing. Psychopharmacology (Berl) 101:519–524

    Article  CAS  Google Scholar 

  • Cummings J, Lefevre G, Small G, Appel-Dingemanse S (2007) Pharmacokinetic rationale for the rivastigmine patch. Neurology 69:S10–S13

    Article  PubMed  CAS  Google Scholar 

  • Dankert ME, Brensinger CM, Metzger KL, Li C, Koleva SG, Mesen A et al (2008) Attitudes of patients and family members towards implantable psychiatric medication. Schizophr Res 105:279–286

    Article  PubMed  Google Scholar 

  • David AS (1990) Insight and psychosis. Br J Psychiatry 156:798–808

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564

    Article  PubMed  CAS  Google Scholar 

  • Delay J, Deniker P, Harl JM, Grasset A (1952a) [N-dimethylamino-prophylchlorophenothiazine (4560 RP) therapy of confusional states]. Ann Med Psychol (Paris) 110:398–403

    CAS  Google Scholar 

  • Delay J, Deniker P, Harl JM (1952b) [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. Ann Med Psychol (Paris) 110:112–117

    CAS  Google Scholar 

  • Dorta MJ, Santovena A, Llabres M, Farina JB (2002) Potential applications of PLGA film-implants in modulating in vitro drugs release. Int J Pharm 248:149–156

    Article  PubMed  CAS  Google Scholar 

  • Edlund U, Albertsson AC (2003) Polyesters based on diacid monomers. Adv Drug Deliv Rev 55:585–609

    Article  PubMed  CAS  Google Scholar 

  • Ereshefsky L, Mascarenas CA (2003) Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 16(Suppl 64):18–23

    Google Scholar 

  • Ereshefsky L, Watanabe MD, Tran-Johnson TK (1989) Clozapine: an atypical antipsychotic agent. Clin Pharm 8:691–709

    PubMed  CAS  Google Scholar 

  • Ezrin-Waters C, Seeman P (1977) Tolerance of haloperidol catalepsy. Eur J Pharmacol 41:321–327

    Article  PubMed  CAS  Google Scholar 

  • Foster J, Brewer C, Steele T (2003) Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 8:211–217

    Article  PubMed  CAS  Google Scholar 

  • Fowler JE Jr, Gottesman JE, Reid CF, Andriole GL Jr, Soloway MS (2000) Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 164:730–734

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231:258–261

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988) An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl) 94:1–7

    Article  CAS  Google Scholar 

  • Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S (2009) D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 34:662–671

    Article  PubMed  CAS  Google Scholar 

  • Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376

    Article  PubMed  CAS  Google Scholar 

  • Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P et al (2004) Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161:692–699

    Article  PubMed  Google Scholar 

  • Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A et al (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35:108–116

    Article  PubMed  CAS  Google Scholar 

  • Harrison PJ (2008) Metabotropic glutamate receptor agonists for schizophrenia. Br J Psychiatry 192:86–87

    Article  PubMed  Google Scholar 

  • Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M (2005) d-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57:577–585

    Article  PubMed  CAS  Google Scholar 

  • Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P et al (2004) A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 65:211–216

    Article  PubMed  Google Scholar 

  • Huang X, Brazel CS (2001) On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 73:121–136

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC, Jotkowitz A, Sircar R, Zukin SR (1987) Non-competitive regulation of phencyclidine/sigma-receptors by the N-methyl-d-aspartate receptor antagonist d-(−)-2-amino-5-phosphonovaleric acid. Neurosci Lett 78:193–198

    Article  PubMed  CAS  Google Scholar 

  • Jain RA (2000) The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475–2490

    Article  PubMed  CAS  Google Scholar 

  • Johnson DA (1981) Long-term maintenance treatment in chronic schizophrenia. Some observations on outcome and duration. Acta Psychiatr Belg 81:161–172

    PubMed  CAS  Google Scholar 

  • Johnson DA (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 45:13–21

    PubMed  CAS  Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087

    Article  PubMed  CAS  Google Scholar 

  • Kalkman HO, Subramanian N, Hoyer D (2001) Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 25:904–914

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW et al (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European neuropsychopharmacology consensus conference in Siena, Italy. Eur Neuropsychopharmacol 8:55–66

    Article  PubMed  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Leucht S, Carpenter D, Docherty JP (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(Suppl 12):5–19

    PubMed  Google Scholar 

  • Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360–369

    Article  PubMed  CAS  Google Scholar 

  • Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553–559

    Article  PubMed  CAS  Google Scholar 

  • Kasper S (2006) Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms. Eur Neuropsychopharmacol 16(Suppl 3):S135–S141

    Article  PubMed  CAS  Google Scholar 

  • Keith S (2006) Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 30:996–1008

    Article  PubMed  CAS  Google Scholar 

  • Keith SJ, Kane JM (2003) Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64:1308–1315

    Article  PubMed  Google Scholar 

  • Keefe RS (2006) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Biol Psychiatry 59:965

    Article  CAS  Google Scholar 

  • Keefe R, Gu H, Perkins D, McEvoy J, Hamer R, Lieberman JA (2005) A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis. ACNP annual meeting, 127

    Google Scholar 

  • Kitchell JP, Wise DL (1985) Poly(lactic/glycolic acid) biodegradable drug–polymer matrix systems. Methods Enzymol 112:436–448

    Article  PubMed  CAS  Google Scholar 

  • Kinon BJ, Stauffer VL, McGuire HC, Kaiser CJ, Dickson RA, Kennedy JS (2003) The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc 4:189–194

    Article  PubMed  Google Scholar 

  • Knox ED, Stimmel GL (2004) Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 26:1994–2002

    Article  PubMed  CAS  Google Scholar 

  • Kohler U, Schroder H, Augustin W, Sabel BA (1994) A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers. Neurosci Lett 170:99–102

    Article  PubMed  CAS  Google Scholar 

  • Kulkarni RK, Pani KC, Neuman C, Leonard F (1966) Polylactic acid for surgical implants. Arch Surg 93:839–843

    Article  PubMed  CAS  Google Scholar 

  • Layman PR, Argyras E, Glynn CJ (1986) Iontophoresis of vincristine versus saline in post-herpetic neuralgia. A controlled trial. Pain 25:165–170

    Article  PubMed  CAS  Google Scholar 

  • Lambert T, Brennan A, Castle D, Kelly DL, Conley RR (2003) Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract 9:252–260

    Article  PubMed  Google Scholar 

  • Langer G, Sachar EJ, Gruen PH, Halpern FS (1977) Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature 266:639–640

    Article  PubMed  CAS  Google Scholar 

  • Lemoine D, Preat V (1998) Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J Control Release 54:15–27

    Article  PubMed  CAS  Google Scholar 

  • Liu FI, Kuo JH, Sung KC, Hu OY (2003) Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies. Int J Pharm 257:23–31

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223

    Article  PubMed  CAS  Google Scholar 

  • Lim ST, Forbes B, Berry DJ, Martin GP, Brown MB (2002) In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm 231:73–82

    Article  PubMed  CAS  Google Scholar 

  • Love RC (2002) Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 59:S10–S15

    PubMed  Google Scholar 

  • Marder SR (2003) Overview of partial compliance. J Clin Psychiatry 64(Suppl 16):3–9

    PubMed  Google Scholar 

  • McEvoy J (2004) The relationship between insight into psychosis and compliance with medications. In: Amador XF, David AS (eds) Insight and psychosis. Oxford University Press, Oxford, pp 311–334

    Google Scholar 

  • McEvoy JP, Applebaum PS, Apperson LJ, Geller JL, Freter S (1989) Why must some schizophrenic patients be involuntarily committed? The role of insight. Compr Psychiatry 30:13–17

    Article  PubMed  CAS  Google Scholar 

  • McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, Geller JL, Roth L (1989a) Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis 177:43–47

    Article  PubMed  CAS  Google Scholar 

  • McEvoy JP, Freter S, Everett G, Geller JL, Appelbaum P, Apperson LJ, Roth L (1989b) Insight and the clinical outcome of schizophrenic patients. J Nerv Ment Dis 177:48–51

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255

    Article  PubMed  CAS  Google Scholar 

  • Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR (2003) Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 54:719–723

    Article  Google Scholar 

  • Metzger KL, Shoemaker JM, Kahn JB, Maxwell CR, Liang Y, Tokarczyk J et al (2007) Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology (Berl) 190:201–211

    Article  CAS  Google Scholar 

  • Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release 125:193–209

    Article  PubMed  CAS  Google Scholar 

  • Nasrallah HA, Lasser R (2006) Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 20:57–61

    Article  PubMed  Google Scholar 

  • Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27–35

    Article  PubMed  CAS  Google Scholar 

  • Nides M (2008) Update on pharmacologic options for smoking cessation treatment. Am J Med 121:S20–S31

    Article  PubMed  CAS  Google Scholar 

  • Nordstrom AL, Farde L, Halldin C (1993) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl) 110:365–367

    Article  CAS  Google Scholar 

  • Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444–1449

    PubMed  CAS  Google Scholar 

  • Oh SH, Lee JY, Ghil SH, Lee SS, Yuk SH, Lee JH (2006) PCL microparticle-dispersed PLGA solution as a potential injectable urethral bulking agent. Biomaterials 27:1936–1944

    Article  PubMed  CAS  Google Scholar 

  • Okada H, Toguchi H (1995) Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 12:1–99

    Article  PubMed  CAS  Google Scholar 

  • Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA (2007) Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry 31:1153–1163

    Article  PubMed  CAS  Google Scholar 

  • Palmer BW, Jeste DV (2006) Relationship of individual cognitive abilities to specific components of decisional capacity among middle-aged and older patients with schizophrenia. Schizophr Bull 32:98–106

    Article  PubMed  Google Scholar 

  • Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102–1107

    Article  PubMed  CAS  Google Scholar 

  • Patrick KS, Straughn AB, Perkins JS, Gonzalez MA (2009) Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol 24:1–17

    Article  PubMed  CAS  Google Scholar 

  • Prausnitz MR, Langer R (2008) Transdermal drug delivery. Nat Biotechnol 26:1261–1268

    Article  PubMed  CAS  Google Scholar 

  • Prausnitz MR, Mitragotri S, Langer R (2004) Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3:115–124

    Article  PubMed  CAS  Google Scholar 

  • Rabin C, Liang Y, Ehrlichman RS, Budhian A, Metzger KL, Majewski-Tiedeken C, Winey KI, Siegel SJ (2008) In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res 98:66–78

    Article  PubMed  CAS  Google Scholar 

  • Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83–89

    PubMed  CAS  Google Scholar 

  • Rabin C, Liang Y, Ehrlichman RS, Budhian A, Metzger KL, Majewski-Tiedeken C et al (2008) In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res 98:66–78

    Article  PubMed  CAS  Google Scholar 

  • Rafati H, Lavelle EC, Coombes AG, Stolnik S, Holland J, Davis SS (1997) The immune response to a model antigen associated with PLG microparticles prepared using different surfactants. Vaccine 15:1888–1897

    Article  PubMed  CAS  Google Scholar 

  • Rittmannsberger H, Pachinger T, Keppelmuller P, Wancata J (2004) Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 55:174–179

    Article  Google Scholar 

  • Sabel BA, Dominiak P, Hauser W, During MJ, Freese A (1990) Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats. J Pharmacol Exp Ther 255:914–922

    PubMed  CAS  Google Scholar 

  • Saggini R, Zoppi M, Vecchiet F, Gatteschi L, Obletter G, Giamberardino MA (1996) Comparison of electromotive drug administration with ketorolac or with placebo in patients with pain from rheumatic disease: a double-masked study. Clin Ther 18:1169–1174

    Article  PubMed  CAS  Google Scholar 

  • Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 64:145–152

    Article  PubMed  CAS  Google Scholar 

  • Sedvall G (1980) Relationships among biochemical, clinical, and pharmacokinetic variables in neuroleptic-treated schizophrenic patients. Adv Biochem Psychopharmacol 24:521–528

    PubMed  CAS  Google Scholar 

  • Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219

    Article  PubMed  CAS  Google Scholar 

  • Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72:4376–4380

    Article  PubMed  CAS  Google Scholar 

  • See RE, Ellison G (1990) Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats. Psychopharmacology (Berl) 100:404–412

    Article  CAS  Google Scholar 

  • Seeman P, Corbett R, Van Tol HH (1997) Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16:93–110, discussion 111–135

    Article  PubMed  CAS  Google Scholar 

  • Sharma R, Saxena D, Dwivedi AK, Misra A (2001) Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 18:1405–1410

    Article  PubMed  CAS  Google Scholar 

  • Sharon AC, Wise DL (1981) Development of drug delivery systems for use in treatment of narcotic addiction. NIDA Res Monogr 28:194–213

    PubMed  CAS  Google Scholar 

  • Shen WW (1999) A history of antipsychotic drug development. Compr Psychiatry 40:407–414

    Article  PubMed  CAS  Google Scholar 

  • Siegel SJ, Winey KI, Gur RE, Lenox RH, Bilker WB, Ikeda D et al (2002) Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology 26:817–823

    Article  PubMed  CAS  Google Scholar 

  • Siegel SJ, Irani F, Brensinger CM, Kohler CG, Bilker WB, Ragland JD et al (2006) Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry 163:433–441.

    Article  PubMed  Google Scholar 

  • Siegel SJ, Kahn JB, Metzger K, Winey KI, Werner K, Dan N (2006) Effect of drug type on the degradation rate of PLGA matrices. Eur J Pharm Biopharm 64:287–293

    Article  PubMed  CAS  Google Scholar 

  • Sodhi M, Wood KH, Meador-Woodruff J (2008) Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Rev Neurother 8:1389–1406

    Article  PubMed  CAS  Google Scholar 

  • Spiers ID, Eyles JE, Baillie LW, Williamson ED, Alpar HO (2000) Biodegradable microparticles with different release profiles: effect on the immune response after a single administration via intranasal and intramuscular routes. J Pharm Pharmacol 52:1195–1201

    Article  PubMed  CAS  Google Scholar 

  • Svensson TH (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145–1158

    Article  PubMed  CAS  Google Scholar 

  • Tandon R, Targum SD, Nasrallah HA, Ross R (2006) Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract 12:348–363

    Article  PubMed  Google Scholar 

  • Tanner T, Marks R (2008) Delivering drugs by the transdermal route: review and comment. Skin Res Technol 14:249–260

    Article  PubMed  CAS  Google Scholar 

  • Torche AM, Le Corre P, Albina E, Jestin A, Le Verge R (2000) PLGA microspheres phagocytosis by pig alveolar macrophages: influence of poly(vinyl alcohol) concentration, nature of loaded-protein and copolymer nature. J Drug Target 7:343–354

    Article  PubMed  CAS  Google Scholar 

  • Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL (1998) Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 155:505–508

    PubMed  CAS  Google Scholar 

  • Tsai GE, Yang P, Chang YC, Chong MY (2006) d-Alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59:230–234

    Article  PubMed  CAS  Google Scholar 

  • Turner MS, Stewart DW (2006) Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 20:20–37

    Article  PubMed  Google Scholar 

  • Vadalouca A, Siafaka I, Argyra E, Vrachnou E, Moka E (2006) Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann NY Acad Sci 1088:164–186

    Article  PubMed  CAS  Google Scholar 

  • Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S (2001) Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin psychiatry 62:545–551

    Article  PubMed  CAS  Google Scholar 

  • Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L et al (2004) Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 30:255–264

    Article  PubMed  Google Scholar 

  • Venkatraman S, Gale R (1998) Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Biomaterials 19:1119–1136

    Article  PubMed  CAS  Google Scholar 

  • Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 54:49–55

    Article  PubMed  CAS  Google Scholar 

  • Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21:419–429

    Article  PubMed  CAS  Google Scholar 

  • Witt C, Kissel T (2001) Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: is the erosion controlled by degradation, swelling or diffusion? Eur J Pharm Biopharm 51:171–181

    Article  PubMed  CAS  Google Scholar 

  • Witt C, Mader K, Kissel T (2000) The degradation, swelling and erosion properties of biodegradable implants prepared by extrusion or compression moulding of poly(lactide-co-glycolide) and ABA triblock copolymers. Biomaterials 21:931–938

    Article  PubMed  CAS  Google Scholar 

  • Zygmunt A, Olfson M, Boyer CA, Mechanic D (2002) Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 159:1653–1664

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Child Psychiatry Branch, National Institute of Mental Health, Bethesda, MD, 20892, USA

    Cara R. Rabin

  2. Translational Neuroscience Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Steven J. Siegel

Authors
  1. Cara R. Rabin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven J. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven J. Siegel .

Editor information

Editors and Affiliations

  1. , Dept. of Psychiatry - MC 0804, University of San Diego, Gilman Drive 9500, La Jolla, 92093, USA

    Neal R. Swerdlow

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer

About this chapter

Cite this chapter

Rabin, C.R., Siegel, S.J. (2010). Antipsychotic Dosing and Drug Delivery. In: Swerdlow, N. (eds) Behavioral Neurobiology of Schizophrenia and Its Treatment. Current Topics in Behavioral Neurosciences, vol 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2010_46

Download citation

Publish with us

Policies and ethics

Search

Navigation